Your session is about to expire
← Back to Search
KER-050 for Anemia in Myelodysplastic Syndromes
Study Summary
This triallooks at how a drug, KER-050, can help treat anemia in patients with myelodysplastic syndrome (MDS).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use effective birth control methods.I started treatment to remove excess iron from my body less than 8 weeks ago.I can care for myself, but my anemia affects my daily activities.I have been treated with specific medications like azacitidine or lenalidomide.My condition is a type of blood cancer classified as low to intermediate risk.I have anemia and meet the specific blood transfusion criteria.I have taken Vitamin B12 within the last 8 weeks.I have not taken any blood cell growth boosters in the last 28 days.I haven't needed IV antibiotics in the last 28 days or oral antibiotics in the last 14 days.I haven't taken any experimental drugs or treatments within the last 28 days or 5 times their half-life period.My kidney function is low, with a GFR less than 40 mL/min.My MDS was caused by previous cancer treatments.
- Group 1: KER-050 Cohort 2
- Group 2: KER-050 Cohort 1
- Group 3: KER-050 Cohort 3
- Group 4: KER-050 Dose Confirmation Cohort
- Group 5: KER-050 Cohort 4
- Group 6: KER-050 Cohort 5
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the patient enrolment for this clinical trial?
"That is correct. The online database shows that this study is looking for volunteers and was last updated on November 14th, 2020. 110 individuals are needed from a single location."
Are there any open positions in this clinical trial?
"That is correct. The latest information on clinicaltrials.gov suggests that this study is looking for 110 individuals to participate between 1 locations. This particular trial was originally posted on 8/19/2020 and was last edited on 11/14/2022."
What have been the reported dangers associated with KER-050 Cohort 2?
"KER-050 Cohort 2's safety is estimated to be a 2. This drug is in Phase 2, meaning that while there is evidence suggesting it won't cause too many adverse effects, there is no data yet supporting its efficacy."
Share this study with friends
Copy Link
Messenger